Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this systematic review, oral minoxidil was found to be a safe and effective treatment for androgenetic alopecia and alopecia areata, with additional benefits for female pattern hair loss and other types of alopecia, although common side effects included hypertrichosis and postural hypotension.

In this study, oral steroid pulse therapy was found to be as effective and well-tolerated as intravenous pulse therapy in treating severe alopecia areata, especially when started within one year of disease onset.

In this study, low-dose finasteride (2.5 mg/day) significantly reduced hirsutism scores in women over 12 months without significant hormonal changes or serious side effects.

This study found that alpha-tocopherol acetate did not demonstrate any protective effect against hair loss induced by doxorubicin in patients with solid tumors.

This study found that a series of three monthly courses of medium-dose prednisolone pulse therapy was effective and well tolerated in most patients with active, multifocal alopecia areata but not in those with totalis/universalis.

This study reported that high-dose mizoribin therapy may be effective and safe for managing steroid-dependent pediatric systemic lupus erythematosus but requires monitoring of serum uric acid levels due to potential side effects.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

This article is a letter to the editor about high-dose pulsed corticosteroid therapy combined with methotrexate for severe childhood alopecia areata and provides no new clinical results.

This study reported that low-dose oral minoxidil is generally safe for treating various types of hair loss, though it may cause hypertrichosis and pedal edema, especially at higher doses.

In this retrospective study, low-dose methotrexate was observed to be effective and well-tolerated in treating recalcitrant alopecia areata multiplex, achieving complete or near-complete hair regrowth in about 90% of patients despite some experiencing elevated liver enzymes and gastrointestinal discomfort.

This study found that corticosteroid pulse therapy may be more effective than oral cyclosporine with corticosteroid for patients with severe alopecia areata, especially for those with the plurifocal type or a short disease duration.

This study found that the herbal combination PRO 160/120 significantly improved nocturnal voiding frequency in patients with moderate-to-severe LUTS/BPH compared to placebo, with similar effectiveness to tamsulosin and finasteride.

This study found that in mice, low-dose irradiation causes stem cells in hair follicles to undergo chromatin alterations, which may eventually lead to long-term functional loss in tissues or organs.

Low-dose oral minoxidil effectively treats female hair loss with good safety.

This study found that 14 days of low-dose aspirin reduced the predicted response to topical minoxidil in androgenetic alopecia patients from 50% to 27%, suggesting aspirin may inhibit minoxidil efficacy.

In this study, low-dose spironolactone effectively reduced hirsutism in women and stopped hair loss in one woman with alopecia areata, without significant side effects over 12 menstrual cycles.

High doses of cyclosporine A increase testosterone conversion, possibly boosting hair growth.

In this study, researchers found no evidence of increased prevalence of pericardial effusions in alopecia patients treated with low-dose oral minoxidil compared to those not receiving minoxidil, based on point-of-care ultrasound evaluations.

This research letter reports that low-dose oral minoxidil improved hair density and length in children with loose anagen hair syndrome.

This letter discusses the limited adaptation of low dose oral minoxidil for androgenetic alopecia in North America and reports no new clinical results; the authors suggest safety concerns or unclear dosing may be factors.

This study found that isolated red light may serve as an alternative for photo-immunotherapy without additional photosensitizers, as it did not reduce keratinocyte differentiation markers or increase photo-oxidative damage, unlike treatment with IL-4 or UVA1/blue light.

This study observed eyebrow regrowth in 7 patients with frontal fibrosing alopecia treated with low-dose oral minoxidil, suggesting it may be a promising treatment option, especially in early disease stages.

In this study, low-dose oral minoxidil was found to improve hair density in 80% of pediatric patients with androgenetic alopecia or telogen effluvium, with mild side effects primarily reported.

This study reported that a subcutaneous injection formulation using PLGA microspheres to release finasteride stably achieved sustained monthly drug delivery without burst release in beagle dogs, with a dose of 16.8 mg identified as optimal for potential first-in-human trials.

This letter discusses adverse events related to low-dose oral minoxidil for alopecia, highlighting age-related risks and stressing the importance of contraindication awareness with no new clinical results presented.

This article reflects on the history and significance of the FDA's approval of topical minoxidil for treating androgenetic alopecia in men and women, dating back to 1988 and 1991 respectively.

Low-dose oral minoxidil does not cause tachycardia in hair loss patients.

This case report describes a patient with permanent chemotherapy-induced alopecia who experienced full hair regrowth after treatment with low-dose oral minoxidil.

Low-dose oral minoxidil increases hair density and thickness in people with hair loss.

This article discusses the potential of low-dose naltrexone as an adjuvant therapy for trichodynia in alopecias, noting its anti-inflammatory properties and need for further research.